Regencell Bioscience Holdings (RGC) Common Equity (2020 - 2025)

Regencell Bioscience Holdings has reported Common Equity for 6 years, with the latest figure at $4.9 million in Q2 2025.

• For the quarter ending Q2 2025, Common Equity fell 40.86% year-over-year to $4.9 million; the trailing twelve-month figure through Jun 2025 stood at $4.9 million (down 40.86% YoY), and the FY2025 full-year result was $4.9 million, down 40.86% from the prior year.
• Common Equity for Q2 2025 stood at $4.9 million, down from $8.2 million in the prior quarter.
• The five-year high for Common Equity was $17.1 million in Q2 2022, with the low at -$4.0 million in Q2 2021.
• Historically, Common Equity has averaged $7.6 million across 5 years, with a median of $8.2 million in 2024.
• Annual changes were most pronounced in 2021 — Common Equity tumbled 50.8% — and 2022, when it surged 527.27%.
• Regencell Bioscience Holdings' Common Equity stood at -$4.0 million in 2021, then surged by 527.27% to $17.1 million in 2022, then retreated by 29.81% to $12.0 million in 2023, then sank by 31.45% to $8.2 million in 2024, then slumped by 40.86% to $4.9 million in 2025.
• The last three Common Equity figures came in at $4.9 million (Q2 2025), $8.2 million (Q2 2024), and $12.0 million (Q2 2023), per Business Quant data.